报价延迟最少15分钟:2026/04/21 21:21 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.67 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.49/-0.62
|
|
企业价值
238.98M
|
| 资产负债 |
|
每股账面净值
1.31
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics. |
